VisiRose Introduces Revolutionary Therapy for Severe Eye Infections
Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals
KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI). VisiRose, a newly launched company of Provectus Biopharmaceuticals (OTCQB:PVCT) and the University, is focused on commercializing this innovative ocular research by combining a formulation of Provectus's pharmaceutical-grade bioactive synthetic small molecule Rose Bengal Sodium (RBS) and BPEI's light-based medical device to treat eye infections caused by bacteria, fungi, and parasites.
RB PDAT offers a potential solution to the growing global problem of antimicrobial resistance (AMR), providing a broad-spectrum ocular therapy that may be safe, effective, and cost-efficient. The treatment has shown rapid infection resolution and improved patient outcomes in clinical trials across the U.S., India, Brazil, and Mexico.
"RB PDAT is a revolutionary, non-invasive treatment showing remarkable promise for patients with severe infectious keratitis. This innovative therapy harnesses the power of light to combat infection and offers new hope for preserving vision," said Jean-Marie Parel, IngETS-G, Ph.D., FAIMBE, FARVO, Director and co-founder of the Ophthalmic Biophysics Center at BPEI.
Guillermo Amescua, M.D., Professor of Clinical Ophthalmology, Medical Director of the Ocular Microbiology Laboratory, and a board-certified ophthalmologist at BPEI added, "VisiRose is crucial for translating the innovation of RB PDAT from the laboratory to a widely accessible treatment, ultimately benefiting countless patients worldwide."
"VisiRose is the bridge that connects innovation with impact. It enables us to bring the hope of RB PDAT to patients who desperately need it, transforming lives and shaping the future of eye care," said Ed Pershing, Chairman of the Board of Directors of VisiRose and Provectus.
Dominic Rodrigues, Acting CEO of VisiRose added, "RB PDAT offers a beacon of hope for patients facing the threat of vision loss from infectious keratitis. This innovative therapy, with its targeted action and dual benefits, represents a significant advancement in eye care, paving the way for a brighter future for those struggling with this challenging condition."
In more than 500 patients, RB PDAT has shown promising results in treating severe eye infections where traditional therapies have failed. VisiRose is poised to address a significant gap in the $60 billion global ophthalmic market, focusing on regions and populations impacted by rising AMR and the lack of access to effective treatments.
About VisiRose
VisiRose is a newly launched, clinical-stage biotechnology company of the University of Miami and Provectus Biopharmaceuticals, focused on commercializing the Miller School of Medicine's Bascom Palmer Eye Institute and its Ophthalmic Biophysics Center's innovative ocular research using Provectus's bioactive synthetic small molecule Rose Bengal Sodium (RBS). For more information, please visit: https://visirose.com.
About Bascom Palmer Eye Institute
The Bascom Palmer Eye Institute, part of the University of Miami Health System, is consistently ranked #1 in ophthalmology in the U.S. by U.S. News & World Report. Known for its cutting-edge research and clinical excellence, Bascom Palmer provides world-class care across all ophthalmic subspecialties and is at the forefront of developing innovative treatments for eye diseases. With a commitment to advancing both patient care and medical research, it is recognized globally as a leader in ophthalmology. For more information, please visit: https://umiamihealth.org/en/bascom-palmer-eye-institute.
About Provectus Biopharmaceuticals
Provectus Biopharmaceuticals (OTCQB: PVCT) is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of bioactive synthetic small molecules called halogenated xanthenes. The Company's lead molecule is named Rose Bengal Sodium. Provectus's drug platform includes:
Clinical development programs in oncology, dermatology, and ophthalmology,
In vivo proof-of-concept programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers, and
In vitro discovery programs in infectious diseases, tissue regeneration and repair, and several proprietary targets.
Information about the Company's clinical trials can be found at the National Institutes of Health (NIH) registry, www.clinicaltrials.gov. For more information, please visit: www.provectusbio.com.
For Media Inquiries:
VisiRose, Inc.
E: contact@visirose.com
W: visirose.com
Contact:
VisiRose, Inc.
Dominic Rodrigues
Acting Chief Executive Officer
E: rodrigues@visirose.com
SOURCE: VisiRose
View the original press release on accesswire.com
VisiRose

Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Registration Now Open for World of Coffee 2025 in Geneva: The Premier Event for Coffee Professionals6.2.2025 09:00:00 CET | Press Release
Join Over 13,000 Attendees and 430+ Exhibitors at Europe's Largest Specialty Coffee Trade Show GENEVA, SWITZERLAND / ACCESS Newswire / February 6, 2025 / World of Coffee, the essential event for coffee professionals, enthusiasts, and innovators from around the globe will have a 2025 edition in Geneva, Switzerland, at the Palexpo SA, June 26-28. Following the record-breaking success of World of Coffee in Copenhagen, this flagship coffee trade show is set to welcome over 13,000 coffee professionals from 160+ countries for three days of business, networking, and education. Produced by the Specialty Coffee Association (SCA), the trade show and conference are proudly supported by Host Sponsor BTW Water + More; Platinum Sponsor Barista Attitude; Diamond Sponsor Nestlé Professional; and Gold Sponsor Alpro. Café de Colombia will be featured as the Portrait Country with unique cultural activations, and a pop-up café experience. "Geneva is the ideal location for hosting our flagship European tra
Preservica Delivers Actionable Trusted Long-Term Data with New Innovations in AI and Active Digital Preservation6.2.2025 09:00:00 CET | Press Release
BOSTON, MA AND OXFORD, UK / ACCESS Newswire / February 6, 2025 / Preservica, the industry leader in Active Digital Preservation™ archiving, today unveiled a series of groundbreaking innovations to its pioneering platform. These enhancements further simplify and automate the complex task of preserving critical long-term data, ensuring it remains instantly usable, reliable, and trusted for compliance and emerging AI use. With up to a third of digital content needing to be retained long-term (more than 7 years) according to IDC, unreadable or lost data from poor retention policies, obsolete file formats and accidental or intentional change or deletion is not only a serious compliance, reputational and legal risk but also impacts an organization's ability to leverage AI for value creation and process automation. "As digital content continues to rapidly grow in volume and complexity, having a robust and secure foundation of instantly useable, reliable and trusted long-term data has become a
U.S.-Based Blockchain Kadena and Croatian Football Federation (HNS) Partner to Revolutionize Fan Engagement6.2.2025 09:00:00 CET | Press Release
The Agreement Includes Regular Season Play as Well as the 2026 FIFA World Cup 2026 and UEFA EURO 2028 NEW YORK CITY, NEW YORK / ACCESS Newswire / February 6, 2025 / Kadena, the industry leader in scalable blockchain technology, and the Croatian Football Federation (HNS) have announced a groundbreaking partnership to provide a seamless digital fan engagement experience to Croatian national team fans. This partnership will encompass major global football events through 2028, including the 2026 FIFA World Cup and 2028 UEFA Euro Cup.Kadena and The Croatian Football Federation Enter Partnership to Revolutionize Fan Engagement This collaboration will introduce high-visibility activations, access to VIP experiences, and the migration of the HNS ERC-20 fan token, VATRENI, from Polygon to Kadena via the Kinesis Bridge. "The goal with the [VATRENI] token is to push the boundaries of traditional fan engagement opportunities of the past and introduce more of a future-focused fan experience. We're
Glenmorgan Investments On Track to Reach $7 Billion in Assets Under Management6.2.2025 08:00:00 CET | Press Release
Glenmorgan Investments, a leading global investment firm, is excited to announce record capital inflows across both institutional and retail sectors in the first six weeks of 2025. LONDON, UNITED KINGDOM / ACCESS Newswire / February 6, 2025 / The company is on track to surpass $7 billion in assets under management (AUM) by the time it reports its Q1 2025 results, marking a significant milestone in its ongoing growth and success. These impressive inflows come as a direct result of the company's continued dedication to innovative investment strategies, which have garnered strong interest from both institutional investors and individual retail clients. Glenmorgan's diverse portfolio and commitment to delivering exceptional returns have been key drivers in attracting new capital during this record-breaking period. In particular, the company has experienced a significant surge in retail investor participation since the announcement that the highly sought-after Digital Asset Innovation Fund
KALEO Frontman JJ Julius Son and Entrepreneur Robert Wessman to Launch Unique Limited-Edition Wine Collection at WineParis6.2.2025 07:08:00 CET | Press Release
An Icelandic Merger of Music and Winemaking SAINT-CERNIN-DE-LABARDE, DORDOGNE, FRANCE / ACCESS Newswire / February 6, 2025 / JJ Julius Son, acclaimed frontman for the internationally renowned blues-rock band KALEO, and entrepreneur Robert Wessman have joined forces, creating a limited-edition wine collection. This collaboration highlights their shared Icelandic heritage and promises to deliver an exquisite experience for wine enthusiasts and music lovers. The wines were created in the summer of 2024, by JJ and Robert, at the Maison Wessman winery in France, blending countless samples from barrels in the maison's cellar, under the supervision of oenologist Julien Viaud, of Michel Rolland and Associates. JJ and Robert will formally launch the collection on Feb. 10, 2025, at the global trade fair "WineParis." "We are excited to embark on this journey together," said Robert Wessman. "The goal is to create wines that not only delight the palate but also tell a story of friendship and collab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom